GHRP-1 vs Hexarelin.

GHRP-1 is a synthetic heptapeptide, one of the earliest growth hormone-releasing peptides (GHRPs) developed by Cyril Bowers' group in the 1980s and 1990s alongside GHRP-2 and GHRP-6. It is a growth hormone secretagogue, meaning it prompts the pituitary to release the body's own GH rather than being a form of GH itself. It predates the discovery of ghrelin and was one of the pharmacological tools that led researchers to the growth hormone secretagogue receptor (GHS-R1a). It has always been a research compound and was never developed into an approved drug.

Hexarelin (examorelin) is a synthetic hexapeptide growth hormone secretagogue (GHS), structurally derived from the GHRP-6 family of growth hormone-releasing peptides. It is an investigational compound that was studied in the 1990s and 2000s as a potential agent for probing and stimulating growth hormone secretion and, separately, for direct effects on the heart. It is not an approved drug.

GHRP-1 acts as an agonist at GHS-R1a, the receptor later identified as the endogenous ghrelin receptor, which is expressed in the pituitary and hypothalamus. This is a pathway distinct from growth hormone-releasing hormone (GHRH); GHRPs raise GH through a dual action on somatotrophs and on hypothalamic somatostatin and GHRH tone. Because GHRPs were synthesized before ghrelin was identified in 1999, they are best understood as synthetic ghrelin-mimetic secretagogues. The acute receptor mechanism is well characterized in animals and in short human pituitary-response studies.

Hexarelin acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same pituitary/hypothalamic receptor activated by the natural hormone ghrelin. Receptor binding engages Gq/11-phospholipase C signaling, mobilizing intracellular calcium in pituitary somatotrophs and triggering pulsatile growth hormone release; this pathway is distinct from and synergistic with GHRH, and also opposes somatostatin tone. Hexarelin additionally binds CD36, a scavenger receptor expressed in cardiac and vascular tissue, which is the proposed basis for GH-independent cardiovascular effects observed in animal models. Because it is a non-selective secretagogue, it also stimulates ACTH/cortisol and prolactin release to a greater degree than more selective agents.

The GH-releasing activity of GHRP-1 in humans was documented early. Laron, Bowers and colleagues reported in Acta Endocrinologica (1993, PMID 8279223) that intravenous GHRP-1 produced dose-related rises in plasma GH in children and adolescents. That study was an acute endocrine-challenge design: small numbers of participants, single administrations, GH sampled over a few hours, no placebo comparison and no blinding, and no follow-up beyond the sampling window. It answers one question, whether the pituitary responds, and no others. Bowers' wider body of work defined the GHRP class and its combined pituitary and hypothalamic actions, showing that GHRPs act through a receptor separate from the GHRH receptor and that the two stimuli are synergistic when given together. Those experiments formed the pharmacological trail that led to the cloning of GHS-R1a and then to the identification of ghrelin as its natural ligand in 1999 (PMID 10604470). GHRP-1 specifically has far less human data than its siblings GHRP-2 and GHRP-6, and most of its literature consists of acute endocrine-response and animal experiments. GHRP-2 and GHRP-6 accumulated repeat-administration studies, diagnostic use in the assessment of GH deficiency, and observations on appetite and body composition. Ipamorelin, developed later in the same class, was characterized as a more selective secretagogue that raises GH with less accompanying cortisol and prolactin release (PMID 9849822). Nothing comparable exists for GHRP-1, which was largely bypassed once its siblings and then ghrelin itself became the preferred research tools. What is not known is most of it. There are no controlled trials of chronic GHRP-1 use, body composition, or clinical outcomes. There is no published human pharmacokinetic profile for the compound as it is sold, no bioavailability data for routes other than the intravenous administration used in the original studies, no dose-response work extending past the acute GH peak, and no evidence on whether pituitary responsiveness is sustained or subject to tachyphylaxis with repeated exposure. The evidence amounts to proof of mechanism rather than proof of benefit.

Human data exist but are limited to small, short-term, acute physiology studies rather than outcome trials. Acute intravenous hexarelin reliably raised serum growth hormone in healthy volunteers and was compared head-to-head with GH in a controlled human study (Imbimbo/Ghigo group, J Endocrinol Invest 1999, PMID 10342360). Separate small studies reported short-lasting increases in left ventricular ejection fraction and cardiac output in normal subjects, GH-deficient patients, and dilated-cardiomyopathy patients, effects that appeared GH-independent (Bisi/Broglio et al., Endocrine 2001, PMID 11322491). A chronic-administration study found that GH responses desensitized over weeks and characterized effects on the pituitary-adrenal axis and prolactin (Clin Endocrinol 1999, PMID 10341859). Most cardioprotection evidence (CD36-mediated ischemia/reperfusion protection, IL-1 signaling) is preclinical and rodent-based (e.g., Int Heart J 2017, PMID 28321024; review J Geriatr Cardiol 2014, PMID 25278975); none of this advanced to a successful human cardiac outcome trial, and clinical development was discontinued.

Acute administration in the early studies was generally tolerated, but there is no long-term human safety data for GHRP-1. As a GH secretagogue it carries the same theoretical concerns as sustained GH elevation, including insulin resistance and fluid retention, and some GHRPs also raise cortisol and prolactin. Those class effects are documented rather than hypothetical: GHRP-2 and GHRP-6 both stimulate ACTH and cortisol release to a degree that ipamorelin was specifically engineered to avoid, and GHRP-6 is a strong appetite stimulant acting through the same ghrelin receptor. Where GHRP-1 sits on that spectrum has never been mapped in a dedicated human study. The recognized consequences of prolonged growth hormone excess, drawn from acromegaly and from supraphysiological GH use, include carpal tunnel symptoms, arthralgia, peripheral edema, worsened glucose tolerance, and cardiac hypertrophy. None of these have been studied for GHRP-1, because no chronic exposure trial exists. Formal toxicology and carcinogenicity packages for the compound are not present in the public literature, and immunogenicity has not been assessed. A legitimate trial would require serial IGF-1 measurement, fasting glucose and insulin or an oral glucose tolerance test, cortisol and prolactin monitoring, thyroid function testing, and periodic assessment for fluid retention and joint symptoms. None of that monitoring occurs outside a clinical setting. Product sold online as GHRP-1 is unregulated research-grade material of uncertain identity and purity, so a vial may contain a different secretagogue, a degraded or truncated peptide, or residual endotoxin and synthesis solvents, and independent testing of the grey peptide market has repeatedly found mislabeled contents. Its human safety profile is largely uncharacterized.

Documented effects in human studies include hexarelin's lack of GH selectivity: it raises cortisol, ACTH, and prolactin alongside growth hormone, so it does not produce a clean GH signal. A well-described limitation is rapid tachyphylaxis/desensitization, with attenuated GH responses on repeated or continuous dosing demonstrated both in vitro (second-messenger level) and over weeks of human administration. Long-term safety in humans is essentially unknown because no large or extended trials were completed; chronic GHS-driven IGF-1 elevation raises theoretical concerns common to this class (fluid retention, insulin sensitivity changes, and the general caution that growth-promoting signaling could be undesirable in the setting of malignancy), but these are not established for hexarelin specifically. There is no established safety profile for non-clinical/self-administered use.

GHRP-1 has never been approved by the FDA or any major regulator for any indication. It is a research chemical sold only for laboratory use. As a growth hormone secretagogue it is prohibited in sport by WADA.

Hexarelin is investigational and has never received FDA or EMA marketing approval; its clinical development was discontinued. It is prohibited in sport at all times by WADA as a growth hormone secretagogue / GH-releasing peptide under category S2 of the Prohibited List, and it is generally sold only as a research-use-only chemical.